engleski

MOLECULAR MECHANISMS OF THE RENOPROTECTIVE EFFECT OF EMPAGLIFLOZIN ON LLC-PK1 CELLULAR MODEL OF PROXIMAL TUBULAR CELLS

Diabetic nephropathy (DN) is a chronic complication of diabetes mellitus, both type I and type II, which can lead to end-stage renal kidney failure. This research aimed to assess the effects of empagliflozin (SGLT2i) on cell viability and F- actin distribution in the LLC-PK1 model of DN. To mimic DN, cells were exposed to high glucose (HG30 mM) followed by 0, 5 mM H2O2 and a combination of glucose and H2O2 for 24 hours. The cells were treated with different combinations of glucose and empagliflozin (100 and 500 nM) and combinations of glucose, H2O2, and empagliflozin. MTT colorimetric assay and Erythrosin B color exclusion test were used to determine cell viability. F-actin cytoskeleton was visualized with Phalloidin stain and subsequently quantified. MTT results revealed a significant reduction in cell viability when treated with the HG30/H2O2 combination (p<0.001). Cell viability was considerably increased with the addition of empagliflozin 100 and 500 nM to cells treated with HG30 and HG30/H2O2 compared to cells treated with HG30/H2O2 only (p<0.001). Furthermore, empagliflozin in the concentration of 100 nM decreased the total amount of F-actin in HG30 treated cells (p<0.001), while a higher dose of 500 nM had no effect. Cellular viability shows that empagliflozin has protective effects on renal injury, whereas the effect on F-actin structure was dose dependent.

diabetic nephropathy ; LLC-PK1 cells ; empagliflozin

nije evidentirano